FGF-21
Selected indexed studies
- FGF-21 as a novel metabolic regulator. (J Clin Invest, 2005) [PMID:15902306]
- Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis. (Metabolism, 2024) [PMID:39357599]
- FGF-21 as a Potential Biomarker for Mitochondrial Diseases. (Curr Med Chem, 2018) [PMID:29332568]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- FGF-21 as a novel metabolic regulator. (2005) pubmed
- Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis. (2024) pubmed
- FGF-21 as a Potential Biomarker for Mitochondrial Diseases. (2018) pubmed
- FGF-21 fusion proteins ameliorate atopic dermatitis by inhibiting the TLR/TSLP signaling pathway: Anti-inflammatory and skin barrier repair effects. (2025) pubmed
- A Randomized Controlled Trial to Determine the Impact of Resistance Training versus Aerobic Training on the Management of FGF-21 and Related Physiological Variables in Obese Men with Type 2 Diabetes Mellitus. (2024) pubmed
- Targeting fibroblast growth factor (FGF)-21: a promising strategy for metabolic dysfunction-associated steatotic liver disease treatment. (2025) pubmed
- FGF-21: a novel biomarker predicting no-reflow in ST-segment elevation myocardial infarction. (2024) pubmed
- FGF-21 ameliorates essential hypertension of SHR via baroreflex afferent function. (2020) pubmed
- FGF-21 and GDF-15 are increased in migraine and associated with the severity of migraine-related disability. (2023) pubmed
- FGF-21 Conducts a Liver-Brain-Kidney Axis to Promote Renal Cell Carcinoma. (2023) pubmed